PDF icon PDF herunterladen
Semin Thromb Hemost 2011; 37(5): 440-455
DOI: 10.1055/s-0031-1281028
© Thieme Medical Publishers

von Willebrand Disease: Local Diagnosis and Management of a Globally Distributed Bleeding Disorder

Emmanuel J. Favaloro1
  • 1Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, NSW, Australia
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
18. November 2011 (online)

   Lizenzen und Reprints
Preview

ABSTRACT

von Willebrand disease (VWD) is the most common inherited bleeding disorder and arises from deficiencies and/or defects in the plasma protein von Willebrand factor (VWF). The current report overviews the diagnosis and management of VWD as reflected by differential processes applied within centers around the world. The prevalence of VWD, as well as the frequency of different VWD types, is also reported. VWD prevalence data varies according to methodology used, with epidemiological/population screening estimates approximating 1% of the population (or 10,000 cases per million population), several orders of magnitude higher than estimates from bleeding disorders registry data or regional/center analysis (which instead range from <1 to ~450 cases per million population). Frequency of different VWD types also varies according to source and analysis, with type 1 VWD identified as the clear dominant type in most developed countries (ranging from 40% to 90% of all VWD cases), whereas type 3 VWD predominates in developing countries such as India and Iran. The frequency of qualitative (i.e., type 2) VWD also varies considerably among different reports, ranging from 3% to >50% of all VWD cases, as does the frequency of specific qualitative VWD types (i.e., 2A, 2B, 2M, and 2N). Although type 2A VWD is considered the most common form of type 2 VWD, in some reports workers consider type 2M VWD to be as, or more, common. Although not considered to be a “true” VWD, given its platelet origin, platelet-type VWD is only rarely identified. Finally, management of VWD also differs according to geographic region. Most developed countries use standard therapy, employing desmopressin (DDAVP) wherever possible, factor concentrate in other situations, and antifibrinolytic therapy as required. In contrast, the relative high cost and unavailability of factor concentrates in developing countries, and sometimes the unavailability of DDAVP, requires different management strategies to be applied.

KEYWORDS

von Willebrand disease - VWD - diagnosis - management - desmopressin - DDAVP - genetic testing - factor concentrates

REFERENCES

  • 1 Casonato A, Daidone V, Padrini R. Assessment of von Willebrand factor propeptide improves the diagnosis of von Willebrand disease.  Semin Thromb Hemost. 2011;  37 (5) 456-463
    Suche in Google Scholar
  • 2 Othman M. Platelet-type von Willebrand disease: a rare, often misdiagnosed and underdiagnosed bleeding disorder.  Semin Thromb Hemost. 2011;  37 (5) 464-469
    Suche in Google Scholar
  • 3 Hamilton A, Ozelo M, Leggo J et al.. Frequency of platelet type versus type 2B von Willebrand disease: an international registry-based study.  Thromb Haemost. 2011;  105 (3) 501-508
    Suche in Google Scholar
  • 4 Hampshire D J, Goodeve A C. The International Society on Thrombosis and Haematosis von Willebrand disease database: an update.  Semin Thromb Hemost. 2011;  37 (5) 470-479
    Suche in Google Scholar
  • 5 de Wee E M, Leebeek F WG, Eikenboom JCJ. Diagnosis and management of von Willebrand disease in the Netherlands.  Semin Thromb Hemost. 2011;  37 (5) 480-487
    Suche in Google Scholar
  • 6 Keeney S, Collins P, Cumming A, Goodeve A, Pasi J. Diagnosis and management of von Willebrand disease in the United Kingdom.  Semin Thromb Hemost. 2011;  37 (5) 488-494
    Suche in Google Scholar
  • 7 Lassila R, Holme P A, Landorph A, Petrini P, Önundarson P T, Hillarp A. Nordic Haemophilia Council's practical guidelines on diagnosis and management of von Willebrand disease.  Semin Thromb Hemost. 2011;  37 (5) 495-502
    Suche in Google Scholar
  • 8 Batlle J, Perez-Rodriguez A, Prego JCP, Fraga E L, Rodriguez-Trillo A, Lopez-Fernandez M F. on behalf of participant investigators and centres . Diagnosis and management of von Willebrand disease in Spain.  Semin Thromb Hemost. 2011;  37 (5) 503-510
    Suche in Google Scholar
  • 9 Federici A B, Bucciarelli P, Castaman G, Baronciani L, Canciani M T, Mazzucconi M G, Morfini M, Rocino A, Schiavoni M, Oliovecchio E, Iorio A, Mannucci P M. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1,234 patients.  Semin Thromb Hemost. 2011;  37 (5) 511-521
    Suche in Google Scholar
  • 10 James P D, Lillicrap D P. The diagnosis and management of von Willebrand disease in Canada.  Semin Thromb Hemost. 2011;  37 (5) 522-527
    Suche in Google Scholar
  • 11 Flood V H, Gill J C, Bellissimo D B, Haberichter S L, Friedman K D, Montgomery R R. von Willebrand disease in the United States: a perspective from Wisconsin.  Semin Thromb Hemost. 2011;  37 (5) 528-534
    Suche in Google Scholar
  • 12 Rodgers S E, Lloyd J V, Mangos H M, Duncan E M, McRae S J. Diagnosis and management of adult patients with von Willebrand disorder in South Australia.  Semin Thromb Hemost. 2011;  37 (5) 535-541
    Suche in Google Scholar
  • 13 Favaloro E J, Bonar R, Favaloro J, Koutts J. Diagnosis and management of von Willebrand disease in Australia.  Semin Thromb Hemost. 2011;  37 (5) 542-554
    Suche in Google Scholar
  • 14 Rajagopal R, Smith M P. Diagnosis of von Willebrand disease in South Island, New Zealand.  Semin Thromb Hemost. 2011;  37 (5) 555-559
    Suche in Google Scholar
  • 15 Bonduel M, Frontroth J P, Hepner M, Sciuccati G, Feliu-Torres A, Pieroni G. von Willebrand disease in children: diagnosis and management of a pediatric cohort in one single center in Argentina.  Semin Thromb Hemost. 2011;  37 (5) 560-567
    Suche in Google Scholar
  • 16 Woods A I, Luceros A S, Meschengieser S S, Kempfer A C, Blanco A N, Lazzari M A. Diagnosis and management of von Willebrand disease in a single institution of Argentina.  Semin Thromb Hemost. 2011;  37 (5) 568-575
    Suche in Google Scholar
  • 17 Meiring M, Coetzee M, Kelderman M, Badenhorst P. Laboratory diagnosis and management of von Willebrand disease in South Africa.  Semin Thromb Hemost. 2011;  37 (5) 576-580
    Suche in Google Scholar
  • 18 Akin M, Kavakli K. Laboratory diagnosis and management of von Willebrand disease in Turkey: Izmir experience.  Semin Thromb Hemost. 2011;  37 (5) 581-586
    Suche in Google Scholar
  • 19 Nair S C, Viswabandya A, Srivastava A. Diagnosis and management of von Willebrand disease (VWD): a developing country perspective.  Semin Thromb Hemost. 2011;  37 (5) 581-586
    Suche in Google Scholar
  • 20 Ghosh K, Shetty S. Epidemiology, diagnosis and management of von Willebrand disease in India.  Semin Thromb Hemost. 2011;  37 (5) 595-601
    Suche in Google Scholar
  • 21 Cohan N, Karimi M. Diagnosis and management of von Willebrand disease in Iran.  Semin Thromb Hemost. 2011;  37 (5) 602-606
    Suche in Google Scholar
  • 22 Xu J, Yu Z, Zhang L, Ruan C, Yang R. Diagnosis and management of von Willebrand disease in China.  Semin Thromb Hemost. 2011;  37 (5) 607-614
    Suche in Google Scholar
  • 23 Sadler J E, Budde U, Eikenboom J C Working Party on von Willebrand Disease Classification et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.  J Thromb Haemost. 2006;  4 (10) 2103-2114
    Suche in Google Scholar
  • 24 Favaloro E J. Identification and functional characterisation of von Willebrand disease.  US Hematology. 2009;  2 (1) 16-23
    Suche in Google Scholar
  • 25 Favaloro E J. Toward a new paradigm for the identification and functional characterization of von Willebrand disease.  Semin Thromb Hemost. 2009;  35 (1) 60-75
    Suche in Google Scholar
  • 26 Favaloro E J. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult.  Semin Thromb Hemost. 2007;  33 (8) 727-744
    Suche in Google Scholar
  • 27 Favaloro E J, Krigstein M, Koutts J, Brighton T, Lindeman R. Genetic testing for the diagnosis of von Willebrand disease: benefits and limitations.  J Coag Disorders. 2010;  2 37-47
    Suche in Google Scholar
  • 28 Favaloro E J. Genetic testing for von Willebrand disease: the case against.  J Thromb Haemost. 2010;  8 (1) 6-12
    Suche in Google Scholar
  • 29 Rodeghiero F, Tosetto A, Abshire T ISTH/SSC joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders.  J Thromb Haemost. 2010;  8 (9) 2063-2065
    Suche in Google Scholar
  • 30 Favaloro E J, Lippi G, Franchini M. Contemporary platelet function testing.  Clin Chem Lab Med. 2010;  48 (5) 579-598
    Suche in Google Scholar
  • 31 Othman M, Favaloro E J. Genetics of type 2B von Willebrand disease: “true 2B,” “tricky 2B,” or “not 2B.” What are the modifiers of the phenotype?.  Semin Thromb Hemost. 2008;  34 (6) 520-531
    Suche in Google Scholar
  • 32 Federici A B, Mannucci P M, Castaman G et al.. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients.  Blood. 2009;  113 (3) 526-534
    Suche in Google Scholar
  • 33 Frontroth J P, Hepner M, Sciuccati G, Feliú Torres A, Pieroni G, Bonduel M. Prospective study of low-dose ristocetin-induced platelet aggregation to identify type 2B von Willebrand disease (VWD) and platelet-type VWD in children.  Thromb Haemost. 2010;  104 (6) 1158-1165
    Suche in Google Scholar
  • 34 Ribba A S, Loisel I, Lavergne J M et al.. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen.  Thromb Haemost. 2001;  86 (3) 848-854
    Suche in Google Scholar
  • 35 Riddell A F, Gomez K, Millar C M et al.. Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor.  Blood. 2009;  114 (16) 3489-3496
    Suche in Google Scholar
  • 36 Flood V H, Lederman C A, Wren J S et al.. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD.  J Thromb Haemost. 2010;  8 (6) 1431-1433
    Suche in Google Scholar
  • 37 Melo-Nava B M, Benítez H, Palacios J J et al.. Molecular study of VWF gene from Mexican mestizo patients with von Willebrand disease, and the finding of three new mutations.  Blood Cells Mol Dis. 2007;  39 (3) 361-365
    Suche in Google Scholar
  • 38 Favaloro E J, Mohammed S, Koutts J. Identification and prevalence of von Willebrand disease type 2N (Normandy) in Australia.  Blood Coagul Fibrinolysis. 2009;  20 (8) 706-714
    Suche in Google Scholar
  • 39 Favaloro E J. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin?.  Semin Thromb Hemost. 2008;  34 (1) 113-127
    Suche in Google Scholar
  • 40 Sadler J E. Low von Willebrand factor: sometimes a risk factor and sometimes a disease.  Hematology (Am Soc Hematol Educ Program). 2009;  106-112
    Suche in Google Scholar
  • 41 Favaloro E J, Thom J, Baker R. Australasian Society for Thrombosis and Haemostasis (ASTH) Emerging Technologies Group . Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disorder: results from the second Australasian multi-laboratory survey.  Blood Coagul Fibrinolysis. 2000;  11 (8) 729-737
    Suche in Google Scholar
  • 42 Favaloro E J, Bonar R, Marsden K. on behalf of the RCPA QAP Haemostasis Committee . Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification.  Clin Lab Sci. 2008;  21 (3) 178-183
    Suche in Google Scholar
  • 43 Favaloro E J, Lippi G, Adcock D M. Preanalytical and postanalytical variables: the leading causes of diagnostic error in hemostasis?.  Semin Thromb Hemost. 2008;  34 (7) 612-634
    Suche in Google Scholar
  • 44 Favaloro E J, Bonar R, Meiring M, Street A, Marsden K. RCPA QAP in Haematology . 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD.  Thromb Haemost. 2007;  98 (2) 346-358
    Suche in Google Scholar
  • 45 Favaloro E J, Bonar R, Kershaw G on behalf of the RCPA QAP in Haematology et al. Reducing errors in identification of von Willebrand disease: the experience of the Royal College of Pathologists of Australasia quality assurance program.  Semin Thromb Hemost. 2006;  32 (5) 505-513
    Suche in Google Scholar
  • 46 Favaloro E J. Laboratory identification of von Willebrand disease: technical and scientific perspectives.  Semin Thromb Hemost. 2006;  32 (5) 456-471
    Suche in Google Scholar
  • 47 Favaloro E J. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease.  Thromb Haemost. 2010;  104 (5) 1009-1021
    Suche in Google Scholar
  • 48 Meijer P, Haverkate F. An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation.  Semin Thromb Hemost. 2006;  32 (5) 485-491
    Suche in Google Scholar
  • 49 Favaloro E J. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD): a rebuttal.  J Thromb Haemost. 2008;  6 (11) 1999-2001 author reply 2002-2003
    Suche in Google Scholar
  • 50 Rodeghiero F, Castaman G, Tosetto A. Optimizing treatment of von Willebrand disease by using phenotypic and molecular data.  Hematology (Am Soc Hematol Educ Program). 2009;  113-123
    Suche in Google Scholar
  • 51 Favaloro E J, Thom J, Patterson D et al.. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?.  Thromb Res. 2009;  123 (6) 862-868
    Suche in Google Scholar
  • 52 Favaloro E J, Thom J, Patterson D et al.. Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease.  Blood Coagul Fibrinolysis. 2009;  20 (6) 475-483
    Suche in Google Scholar
  • 53 Favaloro E J. Rethinking the diagnosis of von Willebrand disease.  Thromb Res. 2011;  127 (Suppl 2) S17-S21
    Suche in Google Scholar
  • 54 Keeney S, Bowen D, Cumming A, Enayat S, Goodeve A, Hill M. UK Haemophilia Centre Doctors' Organisation (UKHCDO) . The molecular analysis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organisation Haemophilia Genetics Laboratory Network.  Haemophilia. 2008;  14 (5) 1099-1111
    Suche in Google Scholar
  • 55 Stonebraker J S, Bolton-Maggs P H, Soucie J M, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world.  Haemophilia. 2010;  16 (1) 20-32
    Suche in Google Scholar
  • 56 Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease.  Blood. 1987;  69 (2) 454-459
    Suche in Google Scholar
  • 57 Castaman G, Eikenboom J C, Bertina R M, Rodeghiero F. Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation.  Thromb Haemost. 1999;  82 (3) 1065-1070
    Suche in Google Scholar
  • 58 Biron C, Mahieu B, Rochette A et al.. Preoperative screening for von Willebrand disease type 1: low yield and limited ability to predict bleeding.  J Lab Clin Med. 1999;  134 (6) 605-609
    Suche in Google Scholar
  • 59 Werner E J, Broxson E H, Tucker E L, Giroux D S, Shults J, Abshire T C. Prevalence of von Willebrand disease in children: a multiethnic study.  J Pediatr. 1993;  123 (6) 893-898
    Suche in Google Scholar
  • 60 Gürsel T, Kavaklı K, Aktuğlu G et al.. Hemofili ve von Willebrand Hastalığında Tanı ve Tedavi, Türk Hematoloji Derneği-Hemofili Alt Komitesi (Turkish Guideline). İstanbul, Turkey: Rehberi; 1999: 2-5
    Suche in Google Scholar
  • 61 Yilmaz D, Karapınar B, Yeniay B S, Balkan C, Bilenoğlu B, Kavaklı K. İzmir'de von Willebrand Hastalığı sıklığını belirtmeye yönelik epidemiyolojik çalışma [in Turkish].  Ege Pediatri Bülteni. 2005;  12 (3) 151-159
    Suche in Google Scholar
  • 62 Cabrera M E, Artigas C G, Páez E et al.. von Willebrand's disease in the IX Region of Chile.  Rev Med Chil. 1989;  117 (4) 423-430
    Suche in Google Scholar
  • 63 Diez-Ewald M, Vizcaíno G, Arteaga-Vizcaíno M, Fernández N, Weir-Medina J, Gómez O. Epidemiology of von Willebrand's disease in the state of Zulia, Venezuela.  Invest Clin. 1991;  32 (4) 187-199
    Suche in Google Scholar
  • 64 Zhang L, Li H, Zhao H, Zhang X, Ji L, Yang R. Retrospective analysis of 1312 patients with haemophilia and related disorders in a single Chinese institute.  Haemophilia. 2003;  9 (6) 696-702
    Suche in Google Scholar
  • 65 Sadler J E, Mannucci P M, Berntorp E et al.. Impact, diagnosis and treatment of von Willebrand disease.  Thromb Haemost. 2000;  84 (2) 160-174
    Suche in Google Scholar
  • 66 Iorio A, Oliovecchio E, Morfini M, Mannucci P M. Association of Italian Hemophilia Centres Directors . Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis.  Haemophilia. 2008;  14 (3) 444-453
    Suche in Google Scholar
  • 67 Canadian Hemophilia Registry .Available at: http://fhs.mcmaster.ca/chr/data.html Accessed December 27, 2010
  • 68 World Federation for Haemophilia. 2008 Report. Available at: http://www.wfh.org/2/docs/Publications/.../2008_Global_Survey_Report.pdf Accessed February 18, 2011
    Suche in Google Scholar
  • 69 Woods A I, Meschengieser S S, Blanco A N et al.. Clinical features and laboratory patterns in a cohort of consecutive Argentinian patients with von Willebrand's disease.  Haematologica. 2001;  86 (4) 420-427
    Suche in Google Scholar
  • 70 Zhang J Y, Wang Y C, Yang L et al.. Retrospective analysis of 100 patients with von Willebrand disease.  Clin Focus. 2003;  18 581-582
    Suche in Google Scholar
  • 71 Kumar S, Kishore R, Gupta V, Jain M, Shukla J. Prevalence and spectrum of von Willebrand disease in eastern Uttar Pradesh.  Indian J Pathol Microbiol. 2010;  53 (3) 486-489
    Suche in Google Scholar
  • 72 Trasi S, Shetty S, Ghosh K, Mohanty D. Prevalence and spectrum of von Willebrand disease from western India.  Indian J Med Res. 2005;  121 (5) 653-658
    Suche in Google Scholar
  • 73 Rezende S M, Pinheiro K, Caram C, Genovez G, Barca D. Registry of inherited coagulopathies in Brazil: first report.  Haemophilia. 2009;  15 (1) 142-149
    Suche in Google Scholar
  • 74 Tagliaferri A, Rivolta G F, Biasoli C et al.. A web-based registry of inherited bleeding disorders in the region of Emilia-Romagna: results at three and a half years.  Haemophilia. 2008;  14 (2) 343-354
    Suche in Google Scholar
  • 75 Michiels J J, van de Velde A, van Vliet H H, van der Planken M, Schroyens W, Berneman Z. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.  Semin Thromb Hemost. 2002;  28 (2) 111-132
    Suche in Google Scholar
  • 76 Michiels J J, van Vliet H H, Berneman Z et al.. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.  Clin Appl Thromb Hemost. 2007;  13 (1) 14-34
    Suche in Google Scholar
  • 77 Federici A B, Mazurier C, Berntorp E et al.. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study.  Blood. 2004;  103 (6) 2032-2038
    Suche in Google Scholar
  • 78 Lee C A, Hubbard A, Sabin C A on behalf of the ISTH-SSC sub-committee on VWF et al. Laboratory diagnosis of von Willebrand disease: results from a prospective and blind study in 32 laboratories worldwide using lyophilized plasmas.  J Thromb Haemost. 2010;  9 220-222
    Suche in Google Scholar

Emmanuel J FavaloroPh.D. F.F.Sc. (RCPA) 

Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR)

Westmead Hospital, Westmead, NSW, 2145, Australia

eMail: emmanuel.favaloro@swahs.health.nsw.gov.au